Urgent

Venous thromboembolism in pregnancy & puerperium — DVT and thromboprophylaxis

Pregnancy/postpartum is prothrombotic; VTE is a leading direct cause of maternal death. Covers DVT diagnosis, LMWH treatment and risk-based prophylaxis (RCOG GTG 37a/b). DRAFT for clinician review. (PE in pregnancy has a separate entry.) · Obstetric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pregnancy and the 6 weeks postpartum carry a several-fold increased VTE risk (venous stasis, hypercoagulability, left-sided iliofemoral DVT predominance). Have a low threshold to investigate and to start treatment-dose low-molecular-weight heparin (LMWH) while awaiting imaging. D-dimer is unreliable in pregnancy and should not be used to exclude VTE. LMWH is the anticoagulant of choice (does not cross the placenta); DOACs and warfarin are generally avoided antenatally. Thromboprophylaxis is prescribed by a risk-score at booking, antenatally and postnatally (RCOG Green-top 37a). This entry complements the existing 'Pulmonary embolism in pregnancy' protocol.

Red flags

  • Signs of PE: breathlessness, pleuritic chest pain, tachycardia, hypoxia, collapse (massive PE — resuscitate, see PE entry)
  • Phlegmasia cerulea dolens (massively swollen, dusky, painful leg — limb-threatening iliofemoral DVT)
  • Neurological signs (CVST), severe headache
  • Major bleeding on anticoagulation
  • Heparin-induced thrombocytopenia (falling platelets ~day 5-10)

Assessment

Differential diagnosis

  • Deep vein thrombosis (usually left leg, iliofemoral)
  • Pulmonary embolism (see separate entry)
  • Ruptured Baker's cyst, cellulitis, muscle tear (leg swelling)
  • Superficial thrombophlebitis
  • Lymphoedema / dependent oedema of pregnancy
  • Ovarian vein / pelvic vein thrombosis (postpartum)
  • Cerebral venous sinus thrombosis (if neurological)

Investigations

  • Compression duplex ultrasound of the leg for suspected DVT (repeat in 3-7 days if negative but high clinical suspicion; consider iliac vein imaging/MRI for pelvic DVT)
  • Do NOT use D-dimer to exclude VTE in pregnancy (physiologically raised)
  • Baseline FBC, U&E, LFT, coagulation before starting anticoagulation; booking weight (for dosing)
  • For suspected PE: ECG, CXR, then V/Q or CTPA (see PE-in-pregnancy entry)
  • Thrombophilia testing is generally NOT done acutely (affected by pregnancy/clot/heparin) — defer
  • Assess bleeding risk, renal function (dose adjust LMWH if eGFR low)

Management

  • If VTE clinically suspected, start treatment-dose LMWH immediately unless contraindicated, while arranging imaging (do not wait for the scan)
  • Confirm with compression duplex (DVT) or CTPA/VQ (PE); if imaging negative but suspicion high, repeat/continue per protocol
  • Dose LMWH by early-pregnancy/booking weight; treat as twice-daily or once-daily regimen per local policy; monitor anti-Xa only at extremes of weight/renal impairment
  • Continue therapeutic LMWH for the rest of pregnancy and at least 6 weeks postpartum (minimum 3 months total treatment)
  • Plan peripartum anticoagulation: omit LMWH at onset of labour/planned 24 h before induction or caesarean; neuraxial anaesthesia timing per last dose (e.g. >= 24 h after therapeutic dose)
  • Postnatal: can switch to warfarin or (if not breastfeeding-restricted) LMWH; DOACs generally avoided in breastfeeding [verify local]
  • For prophylaxis: apply RCOG risk assessment at booking, on admission, and postnatally; prescribe weight-banded prophylactic LMWH to those meeting thresholds (e.g. after caesarean, immobility, obesity, prior VTE, thrombophilia)
  • Fit graduated compression stockings; encourage mobility/hydration
  • Provide written information; arrange maternal-medicine/haematology follow-up

Drugs & doses

Enoxaparin treatment dose ~1 mg/kg SC twice daily (or 1.5 mg/kg SC once daily) by booking weight for acute VTE; dalteparin/tinzaparin alternatives [verify local regimen]
Enoxaparin prophylaxis (weight-banded, RCOG GTG 37a): < 50 kg 20 mg, 50-90 kg 40 mg, 91-130 kg 60 mg, 131-170 kg 80 mg SC once daily; > 170 kg ~0.6 mg/kg/day [verify local]
LMWH is the agent of choice in pregnancy (does not cross placenta); AVOID DOACs and warfarin antenatally (warfarin teratogenic)
Reduce LMWH dose / monitor anti-Xa if creatinine clearance < 30 mL/min or weight extremes [verify local]
Unfractionated heparin IV: for high-risk situations near delivery or if rapid reversibility needed (shorter half-life, protamine-reversible)
Protamine sulfate for LMWH-related major bleeding (partial reversal) [verify local dose]
Postnatal: warfarin (safe in breastfeeding) or continue LMWH; apixaban/rivaroxaban generally avoided while breastfeeding [verify local]

Disposition

Admit or manage via ambulatory pathway depending on severity; start LMWH and arrange imaging. Maternal-medicine/haematology and obstetric anaesthetic input for peripartum plan. Prophylaxis prescribed per RCOG risk score across antenatal and postnatal periods. Clear peripartum LMWH-omission and neuraxial-timing plan documented; VTE follow-up and duration of treatment specified.

Complications & pitfalls

  • Pulmonary embolism (potentially fatal)
  • Post-thrombotic syndrome, chronic venous insufficiency
  • Recurrent VTE; pregnancy-associated clot propagation
  • Bleeding from anticoagulation; HIT (rare with LMWH)
  • Heparin-induced osteoporosis (long-term use)

Exam pearls

  • D-dimer does not exclude VTE in pregnancy — image instead.
  • Pregnancy DVT is usually left-sided and iliofemoral; consider pelvic vein imaging if calf scan is negative but suspicion high.
  • Start treatment-dose LMWH on clinical suspicion before the scan; do not wait.
  • LMWH is the anticoagulant of choice; warfarin is teratogenic and DOACs are avoided in pregnancy/breastfeeding.
  • Continue anticoagulation for the whole pregnancy and at least 6 weeks postpartum (minimum 3 months total).
  • Do a documented RCOG VTE risk assessment at booking, on any admission, and postnatally — most maternal PE deaths follow missed prophylaxis.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.